GlaxoSmithKline (GSK)
Global Health Medicines Research & Development (R&D)
Tres Cantos, Spain
Member since 2012
GSK Biologist Eva Maria Lopez in the TB BSL3 Lab
Richard Moran Photography (2018)Representative
Robert Bates, Ph.D. Director, Head of Translational Research
Team
- David Barros
- Beatriz Rodriguez-Miquel
- Modesto Remuiñán
- Carlos Alemparte
- Ruben Gonzalez
- Rocio Canals
- Silvia Gonzalez
- Joaquin Rullas
- Joel Lelievre
- Eugenia Meiler
- And many others…
About
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
And our work to improve Global Health is integral to that purpose.
In Global Health, our ambition is to positively impact the health of more than 1.3 billion people in lower income countries through the prevention and treatment of infectious diseases by the end of this decade. We’re committed to progressing our innovative Global Health pipeline of more than 25 potential new medicines and vaccines, expanding sustainable access to our innovations at scale, and strengthening health systems, in collaboration with our partners.
We are developing multiple new potential treatment options for TB – the world’s biggest infectious disease killer and the cause of more than one third of all deaths attributable to antimicrobial resistant organisms. In 2012, GSK signed on as one of the founding members of the TB Drug Accelerator (TBDA). Since then, we have valued TBDA’s role in creating space for collaboration between industry, academics, and other organizations to drive the discovery of new candidate medicines so we can get ahead of TB. GSK’s dedicated Global Health Medicines R&D unit based in Tres Cantos, Spain, has been able to work through this consortium to progress multiple assets, including GSK2556286, GSK4061830 (also known as DDU384, discovered in partnership with the University of Dundee), and others.
Role & Expertise
GSK’s R&D medicines team is made up of over 100 dedicated scientists encompassing all areas of drug discovery and development: biology, chemistry, and pharmacology. This experienced team has been focused on the discovery of new drugs for Global Health infectious diseases for over 25 years. Facilities include Biosafety Level 3 and 4 laboratories for working with highly infectious agents including Mycobacterium tuberculosis.
GSK’s internal research in Global Health is complemented by the Tres Cantos Open Lab Foundation, which since 2010 has allowed independent researchers to access GSK R&D facilities, resources and expertise to help them advance their own research focused on medicines for endemic infectious diseases.